Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedergoogle.com
Google Alert - HER2-ADC
Get the latest updates from Google Alert - HER2-ADC directly as they happen.
Follow now 123 followers
Latest posts
Last updated about 18 hours ago
TQB2102 Shows Early Activity Across HER2-Expressing Solid Tumors - OncoDaily
about 20 hours ago
TQB2102 HER2 biparatopic ADC showed manageable safety and early antitumor activity in...
Exploratory Classification of Pyrotinib-Containing Neoadjuvant Regimen | BCTT
about 23 hours ago
Adding pyrotinib to an ADC may concurrently suppress residual HER2 ... HER2...
Daiichi emerges from bruising 2 years with vision for cracking cancer's big leagues
1 day ago
The HER2-directed ADC that Daiichi developed with AstraZeneca remains a ... HER2's...
The therapeutic potential of antibody-drug conjugates in advanced colorectal cancer
1 day ago
HER2-targeted antibody-drug conjugates (ADCs) have achieved clinically meaningful activity in several human...
Dual-payload ADC holds promise for treating HER2+ tumors | BioWorld
1 day ago
KEYWORDS AACR 2026 dual-payload ADCs HER2 PLB-015 Primelink Biotherapeutics (Shenzhen) Co...
Merck's TROP2 ADC opens global women's cancer push with endometrial win - BioCentury
2 days ago
Merck's TROP2 ADC, sacituzumab tirumotecan, delivered the week's ... ADCs against FRα...
FDA Grants Priority Review to Frontline Sevabertinib in HER2-Mutant NSCLC
2 days ago
... HER2 therapy, versus ORR 38% and DOR 7.0 months after HER2...
LigaChem Biosciences drives ADC push, prioritizes toxicity control after efficacy - Chosunbiz
3 days ago
LCB14 is a HER2-targeting ADC and is the most advanced in development...
FDA Expands Enhertu into Early HER2-Positive Breast Cancer with Dual New Indications
3 days ago
The approvals reinforce the accelerating adoption of ADCs across oncology and underscore...
AZN, Daiichi's Enhertu Gets FDA Nod for Two New Breast Cancer Settings - TradingView
3 days ago
AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the FDA...
FDA Expands T-DXd With 2 New Indications in HER2-Positive Early Breast Cancer
3 days ago
T-DXd is a HER2-directed ADC that combines trastuzumab with a topoisomerase I...
An update on patent issues regarding antibody–drug conjugates | Nature Biotechnology
3 days ago
A decade on, while the basic principles discussed in the first review...